Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A New Tumor-Immunotherapy Regimen Based on Impulsive Control Strategy Publisher



Aghaeeyan A1 ; Yazdanpanah MJ2 ; Hadjati J3
Authors

Source: Biomedical Signal Processing and Control Published:2020


Abstract

Autologous tumor infiltrating lymphocyte (TIL) therapy refers to a kind of immunotherapy in which the tumor-resident lymphocytes are harvested, cultured, and then transferred into the patient. In spite of some well-known TILs expansion recommendations, there is a lack of well-established TILs injection protocol. This paper addresses the challenge using a feedback-based control strategy. Utilizing Lyapunov technique, a novel dose calculation method is proposed which considers TILs pharmacokinetics. Then, to determine the timing of TILs administration, the concept of therapeutic window in pharmacy is exploited. The resultant therapy protocol is both practical and implementable while it ensures tumor remission. Comparing with previous studies, the proposed method takes the discontinuity of TILs delivery process into consideration. Computational results suggest the following therapy protocol which is in accordance with experimental observations: A few high dose TILs injections are required. Then, there is a longtime drug free interval. © 2019 Elsevier Ltd
Other Related Docs
4. Mathematical Model of Cancer Immunotherapy by Dendritic Cells Combined With Tumor Hypoxia Treatment, 2018 25th Iranian Conference on Biomedical Engineering and 2018 3rd International Iranian Conference on Biomedical Engineering# ICBME 2018 (2018)
5. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
8. Abscopal Effect in Radioimmunotherapy, International Immunopharmacology (2020)
11. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
14. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
15. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)